Dennis J. Church

Corporate Officer/Principal chez Xigen SA

Health Technology

Relations actives

Nom	Sexe	Age	Sociétés liées	Collaboration
Jean-Blaise Eckert	M	61	Xigen SA Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland.	-
Pascal Nicod	M	-	Xigen SA Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland.	-
Elmar Schärli	M	52	Xigen SA Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland.	-
Marc Mathieu	M	-	Xigen SA Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland.	-
Géraldine Dury	M	-	Xigen SA Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland.	-
Sazonov Mikhail	M	-	Xigen SA Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland.	-